Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCarbonell, Cristina
dc.contributor.authorMarcos, Miguel
dc.contributor.authorGuillen Del Castillo, Alfredo
dc.contributor.authorRubio-Rivas, Manuel
dc.contributor.authorArgibay, Ana
dc.contributor.authorMarín Ballvé, Adela
dc.contributor.authorFonollosa Pla, Vicenç
dc.contributor.authorSimeón Aznar, Carmen Pilar
dc.date.accessioned2022-10-24T08:53:28Z
dc.date.available2022-10-24T08:53:28Z
dc.date.issued2022-10
dc.identifier.citationCarbonell C, Marcos M, Guillén-del-Castillo A, Rubio-Rivas M, Argibay A, Marín-Ballvé A, et al. Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE). Autoimmun Rev. 2022 Oct;21(10):103167.
dc.identifier.issn1568-9972
dc.identifier.urihttps://hdl.handle.net/11351/8332
dc.descriptionAnticentromere antibody; Cancer; Systemic sclerosis
dc.description.abstractAim Patients with systemic sclerosis (SSc) are at increased risk of cancer, a growing cause of non–SSc-related death among these patients. We analyzed the increased cancer risk among Spanish patients with SSc using standardized incidence ratios (SIRs) and identified independent cancer risk factors in this population. Material and methods Spanish Scleroderma Registry data were analyzed to determine the demographic characteristics of patients with SSc, and logistic regression was used to identify cancer risk factors. SIRs with 95% confidence intervals (CIs) relative to the general Spanish population were calculated. Results Of 1930 patients with SSc, 206 had cancer, most commonly breast, lung, hematological, and colorectal cancers. Patients with SSc had increased risks of overall cancer (SIR 1.48, 95% CI 1.36–1.60; P < 0.001), and of lung (SIR 2.22, 95% CI 1.77–2.73; P < 0.001), breast (SIR 1.31, 95% CI 1.10–1.54; P = 0.003), and hematological (SIR 2.03, 95% CI 1.52–2.62; P < 0.001) cancers. Cancer was associated with older age at SSc onset (odds ratio [OR] 1.22, 95% CI 1.01–1.03; P < 0.001), the presence of primary biliary cholangitis (OR 2.35, 95% CI 1.18–4.68; P = 0.015) and forced vital capacity <70% (OR 1.8, 95% CI 1.24–2.70; P = 0.002). The presence of anticentromere antibodies lowered the risk of cancer (OR 0.66, 95% CI 0.45–0.97; P = 0.036). Conclusions Spanish patients with SSc had an increased cancer risk compared with the general population. Some characteristics, including specific autoantibodies, may be related to this increased risk.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesAutoimmunity Reviews;21(10)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectAutoanticossos
dc.subjectCàncer - Complicacions
dc.subjectEsclerosi sistemàtica progressiva - Complicacions
dc.subject.meshScleroderma, Systemic
dc.subject.meshNeoplasms
dc.subject.meshAutoantibodies
dc.titleStandardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE)
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.autrev.2022.103167
dc.subject.decsesclerodermia sistémica
dc.subject.decsneoplasias
dc.subject.decsautoanticuerpos
dc.relation.publishversionhttps://doi.org/10.1016/j.autrev.2022.103167
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Carbonell C, Marcos M] Department of Internal Medicine, Hospital Universitario de Salamanca, Universidad de Salamanca-IBSAL, Salamanca, Spain. [Guillén-Del-Castillo A, Fonollosa-Pla V, Simeón-Aznar CP] Unitat de Malalties Autoimmunes, Servei de Medicina Interna, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Rubio-Rivas M] Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. [Argibay A] Unit of Systemic Autoimmune Diseases and Thrombosis, Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo. Vigo, Pontevedra, Spain. [Marín-Ballvé A] Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, IIS Aragón. Zaragoza, Spain
dc.identifier.pmid35931315
dc.identifier.wos000856598500009
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record